History of international connections of myology in Europe

Submitted: 30 April 2023
Accepted: 30 June 2023
Published: 10 July 2023
Abstract Views: 1145
PDF: 205
HTML: 6
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Over the past centuries, myology as a basic and clinical science has passed through three major stages of development: the classical period, the modern nosographic stage, and the molecular era. The classical period spans the sixteenth century up to the earlier parts of the twentieth century. During this time, several major muscle diseases were clinically and pathologically characterized, including Duchenne muscular dystrophy (DMD), myotonic dystrophy, and facio-scapulo-humeral dystrophy, by master clinicians such as Duchenne, Erb, Becker, Steinert, Landouzy, Dejerine, Meryon, and others. These accomplishments laid solid foundations for the following modern era with nosographic classification and the following molecular era. European clinicians and scientists were major contributors to the modern era in the second half of the twentieth century, which is characterized by three major discoveries. First, it was observed that substantial elevation of the serum activity of creatine kinase indicates muscle damage or destruction. Then, the adaptation of modern histo-and cytochemical techniques to the study of muscle biopsies markedly improved the diagnostic accuracy and made possible the identification of new changes and structures. Thirdly, the advent of modern biochemical techniques permitted the identification of various enzyme defects/storage diseases such as Pompe disease, McArdle's disease, and carnitine deficiency states. The molecular era was made possible by the strikingly fast development of molecular biology and its application to muscle diseases. This permitted the identification of gene defects in many inherited diseases, leading to an accurate and specific diagnosis. The growth of international collaboration in Europe was achieved through the exchange of international scientists and collaborative networks.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Angelini C. Handbook of clinical neurology - History of Neurology. In: Finger S, Boller F, Tyler KL, editors. Muscular Dystrophy.2010, Vol. 95. Amsterdam: Elsevier; pp. 477–488. DOI: https://doi.org/10.1016/S0072-9752(08)02131-3
Duchenne de Bologne G. Pseudo-hypertrophic muscular paralysis or myosclerotic paralysis. Extract from the general archives of medicine. Paris: Asselin.1868. (Francoise).
Ladouzy L, Dejerine J. De la myopathie atrophique progressive (myopathie hereditaire, debuttant dans l'enfance par la face, sans alteration du systeme nerveux).Comptes rendu de l'Academie des Sciences, Paris,1884,98,53-55. (Francoise).
Angelini C, Di Mauro S, Margreth A. Relationship of serum enzyme changes to muscle damage in vitamin E deficiency of the rabbit. Sperimentale. 1968 Sep-Oct;118(5):349-69. PMID: 5736127.
Brain. 1963 Dec;86:793-810. DOI: https://doi.org/10.1093/brain/86.4.793
Olson W, Engel WK, Walsh GO, Einaugler R. Oculocraniosomatic neuromuscular disease with "ragged-red" fibers. Arch Neurol. 1972 Mar;26(3):193-211. PMID: 4400816. DOI: https://doi.org/10.1001/archneur.1972.00490090019001
McArdle B. Myopathy due to a defect in muscle glycogen breakdown. Clin Sci. 1951 Feb;10(1):13-35. PMID: 24540673.
Engel AG, Angelini C. Carnitine deficiency of human skeletal muscle with associated lipid storage myopathy: a new syndrome. Science. 1973 Mar 2;179(4076):899-902. PMID: 4687787. DOI: https://doi.org/10.1126/science.179.4076.899
Angelini C. Progress in muscle research through the international congress of neuromuscular diseases (ICNMD): a narrative review. Eur J Transl Myol. 2023 May 5;33(2).. PMID: 37144971. DOI: https://doi.org/10.4081/ejtm.2023.11239
Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987 Dec 24;51(6):919-28. PMID: 3319190. DOI: https://doi.org/10.1016/0092-8674(87)90579-4
Walton JN, Nattrass FJ. On the classification, natural history and treatment of the myopathies. Brain. 1954;77(2):169-231. PMID: 13190076. DOI: https://doi.org/10.1093/brain/77.2.169
Richard I, Broux O, Allamand V, Fougerousse F, Chiannilkulchai N, Bourg N, Brenguier L, Devaud C, Pasturaud P, Roudaut C, et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell. 1995 Apr 7;81(1):27-40. PMID: 7720071. DOI: https://doi.org/10.1016/0092-8674(95)90368-2
Duggan DJ, Gorospe JR, Fanin M, Hoffman EP, Angelini C. Mutations in the sarcoglycan genes in patients with myopathy. N Engl J Med. 1997 Feb 27;336(9):618-24. PMID: 9032047. DOI: https://doi.org/10.1056/NEJM199702273360904
Liu J, Aoki M, Illa I, Wu C, Fardeau M, Angelini C, Serrano C, Urtizberea JA, Hentati F, Hamida MB, Bohlega S, Culper EJ, Amato AA, Bossie K, Oeltjen J, Bejaoui K, McKenna-Yasek D, Hosler BA, Schurr E, Arahata K, de Jong PJ, Brown RH Jr. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet. 1998 Sep;20(1):31-6. PMID: 9731526. DOI: https://doi.org/10.1038/1682
Bashir R, Britton S, Strachan T, Keers S, Vafiadaki E, Lako M, Richard I, Marchand S, Bourg N, Argov Z, Sadeh M, Mahjneh I, Marconi G, Passos-Bueno MR, Moreira Ede S, Zatz M, Beckmann JS, Bushby K. A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat Genet. 1998 Sep;20(1):37-42. PMID: 9731527. DOI: https://doi.org/10.1038/1689
Minetti C, Sotgia F, Bruno C, Scartezzini P, Broda P, Bado M, Masetti E, Mazzocco M, Egeo A, Donati MA, Volonte D, Galbiati F, Cordone G, Bricarelli FD, Lisanti MP, Zara F. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet. 1998 Apr;18(4):365-8. PMID: 9537420. DOI: https://doi.org/10.1038/ng0498-365
Dalakas MC. Inflammatory myopathies. Recent McDonald CM, Campbell C, Torricelli RE, Finkel RS, Flanigan KM, Goemans N, Heydemann P, Kaminska A, Kirschner J, Muntoni F, Osorio AN, Schara U, Sejersen T, Shieh PB, Sweeney HL, Topaloglu H, Tulinius M, Vilchez JJ, Voit T, Wong B, Elfring G, Kroger H, Luo X, McIntosh J, Ong T, Riebling P, Souza M, Spiegel RJ, Peltz SW, Mercuri E; Clinical Evaluator Training Group; ACT DMD Study Group. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Sep 23;390(10101):1489-1498. Epub 2017 Jul 17. PMID: 28728956.2002;88:253-71. PMID: 11908230.
Angelini C, Giaretta L, Marozzo R. An update on diagnostic options and considerations in limb-girdle dystrophies. Expert Rev Neurother. 2018 Sep;18(9):693-703. Epub 2018 Aug 21. PMID: 30084281. DOI: https://doi.org/10.1080/14737175.2018.1508997
Chabbi N; Angelini C; RodriguezAA. An Update of Clinical, Epidemiological, and Psychosocial Features in Gamma-Sarcoglycanopathy. Muscles. 2023, 2(2), 164-176. DOI: https://doi.org/10.3390/muscles2020012
Guglieri M, Bushby K, McDermott MP, Hart KA, Tawil R, Martens WB, Herr BE, McColl E, Speed C, Wilkinson J, Kirschner J, King WM, Eagle M, Brown MW, Willis T, Griggs RC; FOR-DMD Investigators of the Muscle Study Group; Straub V, van Ruiten H, Childs AM, Ciafaloni E, Shieh PB, Spinty S, Maggi L, Baranello G, Butterfield RJ, Horrocks IA, Roper H, Alhaswani Z, Flanigan KM, Kuntz NL, Manzur A, Darras BT, Kang PB, Morrison L, Krzesniak-Swinarska M, Mah JK, Mongini TE, Ricci F, von der Hagen M, Finkel RS, O'Reardon K, Wicklund M, Kumar A, McDonald CM, Han JJ, Joyce N, Henricson EK, Schara-Schmidt U, Gangfuss A, Wilichowski E, Barohn RJ, Statland JM, Campbell C, Vita G, Vita GL, Howard JF Jr, Hughes I, McMillan HJ, Pegoraro E, Bello L, Burnette WB, Thangarajh M, Chang T. Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial. JAMA. 2022 Apr 19;327(15):1456-1468. PMID: 35381069; PMCID: PMC8984930. DOI: https://doi.org/10.1001/jama.2022.4315
van der Ploeg AT, Kruijshaar ME, Toscano A, Laforêt P, Angelini C, Lachmann RH, Pascual Pascual SI, Roberts M, Rösler K, Stulnig T, van Doorn PA, Van den Bergh PYK, Vissing J, Schoser B; European Pompe Consortium. European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. Eur J Neurol. 2017 Jun;24(6):768-e31. Epub 2017 May 6. PMID: 28477382. DOI: https://doi.org/10.1111/ene.13285
Angelini C. Exercise, nutrition and enzyme replacement therapy are efficacious in adult Pompe patients: report from EPOC Consortium. Eur J Transl Myol. 2021 May 3;31(2):9798. PMID: 33942602; PMCID: PMC8274227. DOI: https://doi.org/10.4081/ejtm.2021.9798
McDonald CM, Campbell C, Torricelli RE, Finkel RS, Flanigan KM, Goemans N, Heydemann P, Kaminska A, Kirschner J, Muntoni F, Osorio AN, Schara U, Sejersen T, Shieh PB, Sweeney HL, Topaloglu H, Tulinius M, Vilchez JJ, Voit T, Wong B, Elfring G, Kroger H, Luo X, McIntosh J, Ong T, Riebling P, Souza M, Spiegel RJ, Peltz SW, Mercuri E; Clinical Evaluator Training Group; ACT DMD Study Group. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Sep 23;390(10101):1489-1498. Epub 2017 Jul 17. PMID: 28728956.
Corrado Angelini, Department of Neuroscience, University of Padova, Padua

CURRICULUM VITAE

 

CORRADO ANGELINI, M.D.

 

Education:MD, University of Padova

            FLEX Examination, Minneapolis, 1973

            North Dakota State license Examination (No. 3339), 1973

            California State License Examination (No. A-33174), 1978; renewed 2020

Fellowships:

            Research Fellowship of Muscular Dystrophy Association, 1972

            Senior Fellowship of Muscular Dystrophy Association, 1978

Professional Appointments:

Postgraduate Research Assistant and Associate Mayo Clinic, Rochester, Minnesota, 1970-1972;            Resident in Neurology, Mayo Clinic, Rochester, Minnesota, 1973

            Assistant Professor of Neurology, University of Padova, Italy, 1973-1978

            Associate Professor of Paediatric Neurology, University of Padova, Italy, 1976-1979

Visiting Assistant Professor of Neurology, Reed Neurological Research Center, UCLA Medical School, 1978-1979; University of Colorado Health Sciences Center, Denver 1984

Director Neuromuscular Center, University of Padova, 1980-2011

            Associate Professor of Neurology, University of Padova, Italy, 1980-1993

            Full Professor of Neurology, University of Padova, Italy, 1994- 2011

            Council of PhD Program in Neurosciences, University of Padova, Italy, 2001- present

Director Neurology Residency Program, University of Padova, Italy, 2002- 2011

Consultant Neuromuscular Disorders,IRCCS S.Camillo Hospital.,Venice,Italy,2010-present

Senior Researcher University of Padova,2013-present

Honors:

            Awarded MDA Senior Fellowship, 1978

            Lion Club Milano Host award for Neurological Sciences,1981

Grands Prix Newropeans 2004

Gaetano Conte’s Prize, Kusadasi 2005

Memberships in Scholarly Societies:

Associate member, American Academy of Neurology, 1976

           European Academy of Neurology and ANA.

            Founding Member of WMS

On Editorial Board of Neuromuscular Disorders, Neurological Sciences, Neurology, Acta Myologica, European Journal Translational Myology ,Therapeutic Advances Neurological Disorders.

 

Major Research Interests:

Primary biochemical defects in inherited neuromuscular diseases, clinical trials in muscular dystrophies and DMD, ALS, myasthenia gravis, congenital muscle diseases, carnitine and lipid metabolism. Glycogenoses

How to Cite

Angelini, C. (2023). History of international connections of myology in Europe. European Journal of Translational Myology, 33(3). https://doi.org/10.4081/ejtm.2023.11439